Partial correction of sensitivity to oxidant stress in Friedreich ataxia patient fibroblasts by frataxin-encoding adeno-associated virus and lentivirus vectors

Human Gene Therapy

Volumn 16, Issue 8, 2005, Pages 947-956

  Fleming, Jane ^a   Spinoulas, Afroditi ^a   Zheng, Maolin ^a   Cunningham, Sharon C ^a   Ginn, Samantha L ^b   McQuilty, Robert C ^b   Rowe, Peter B ^a   Alexander, Ian E ^a,c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FRATAXIN; IRON; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR;

ARTICLE; BIOCHEMISTRY; CASE REPORT; CELL LINE; CELL LOSS; CONTROLLED STUDY; DEGENERATIVE DISEASE; EMBRYO; FIBROBLAST; FRIEDREICH ATAXIA; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MITOCHONDRION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PHENOTYPE; REPORTER GENE; SENSORY NERVE CELL; SPINAL GANGLION; VIRUS RECOMBINANT;

ADENOVIRIDAE; DNA, COMPLEMENTARY; EPITHELIAL CELLS; FIBROBLASTS; FRIEDREICH ATAXIA; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELA CELLS; HUMANS; IRON; IRON-BINDING PROTEINS; LENTIVIRUS; MITOCHONDRIA; OXIDATIVE STRESS; PHENOTYPE; TREATMENT OUTCOME;

ADENO-ASSOCIATED VIRUS; ATAXIA; LENTIVIRUS;

EID: 23844514701     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.947     Document Type: Article

References (53)

1. AZZOUZ, M., RALPH, G.S., STORKEBAUM, E., WALMSLEY, L.E., MITROPHANOUS, K.A., KINGSMAN, S.M., CARMELIET, P., and MAZARAKIS, N.D. (2004). VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 413-417.
2. BARRY, S.C., HARDER, B., BRZEZINSKI, M., FLINT, L.Y., SEPPEN, J., and OSBORNE, W.R. (2001). Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum. Gene Ther. 12, 1103-1108.
3. BJORKLUND, A., KIRIK, D., ROSENBLAD, C., GEORGIEVSKA, B., LUNDBERG, C., and MANDEL, R.J. (2000). Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886, 82-98.
4. BOSCH, A., PERRET, E., DESMARIS, N., TRONO, D., and HEARD, J.M. (2000). Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. 11, 1139-1150.
5. BRADLEY, J.L., BLAKE, J.C., CHAMBERLAIN. S., THOMAS, P.K., COOPER, J.M., and SCHAPIRA, A.H. (2000). Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 9, 275-282.
6. CAMPUZANO, V., MONTERMINI, L., MOLTO, M.D., PIANESE, L., COSSEE, M., CAVALCANTI, F., MONROS, E., RODIUS, F., DUCLOS, F., MONTICELLI, A., ZARA, F., CANIZARES, J., KOUTNIKOVA, H., BIDICHANDANI, S.I., GELLERA, C., BRICE, A., TROUILLAS, P., DE MICHELE, G., FILLA, A., DE FRUTOS, R., PALAU, F., PATEL, P.I., DI DONATO, S., MANDEL, J.L., COCOZZA, S., KOENIG, M., and PANDOLFO, M. (1996). Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427.
7. CAMPUZANO, V., MONTERMINI, L., LUTZ, Y., COVA, L., HINDELANG, C., JIRALERSPONG, S., TROTTIER, Y., KISH, S.J., FAUCHEUX, B., TROUILLAS, P., AUTHIER, F.J., DURR, A., MANDEL, J.L., VESCOVI. A., PANDOLFO, M., and KOENIG, M. (1997). Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6, 1771-1780.
8. CONSIGLIO, A., QUATTRINI, A., MARTINO, S., BENSADOUN, J.C., DOLCETTA, D., TROJANI, A., BENAGLIA, G., MARCHESINI, S., CESTARI, V., OLIVERIO, A., BORDIGNON, C., and NALDINI, L. (2001). In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: Correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. 7, 310-316.
9. COSSEE, M., SCHMITT, M., CAMPUZANO, V., REUTENAUER, L., MOUTOU, C., MANDEL, J.L., and KOENIG, M. (1997). Evolution of the Friedreich's ataxia trinucleotide repeat expansion: Founder effect and premutations. Proc. Natl. Acad. Sci. U.S.A. 94, 7452-7457.
10. COSSEE, M., PUCCIO, H., GANSMULLER, A., KOUTNIKOVA, H., DIERICH, A., LEMEUR, M., FISCHBECK, K., DOLLE, P., and KOENIG, M. (2000). Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 9, 1219-1226.
11. DALY, T.M., OHLEMILLER, K.K., ROBERTS, M.S., VOGLER, C.A., and SANDS, M.S. (2001). Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther. 8, 1291-1298.
12. DELATYCKI, M.B., CAMAKARIS, J., BROOKS, H., EVANSWHIPP, T., THORBURN, D.R., WILLIAMSON. R., and FORREST, S.M. (1999). Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann. Neurol. 45, 673-675.
13. DELATYCKI, M.B., WILLIAMSON, B., and FORREST, S.M. (2000). Friedreich ataxia: An overview. J. Med. Genet. 37, 1-8.
14. DULL, T., ZUFFEREY, R., KELLY, M., MANDEL, R.J., NGUYEN, M., TRONO, D., and NALDINI, L. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471.
15. FITZGERALD, M.J.T. (1985). General anatomy and ascending pathways. In Neuroanatomy: Basic and Applied. (Baillière Tindall, London) pp. 60-69.
16. FLEMING, J., GINN, S.L., WEINBERGER, R.P., TRAHAIR, T.N., SMYTHE, J.A., and ALEXANDER, I.E. (2001). Adeno-associated virus and lentivirus vectors mediate efficient and sustained transduction of cultured mouse and human dorsal root ganglia sensory neurons. Hum. Gene Ther. 12, 77-86.
17. FOLLENZI, A., AILLES, L.E., BAKOVIC, S., GEUNA, M., and NALDINI, L. (2000). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25, 217-222.
18. GEY, G.O., COFFMAN, W.D., and KUBICEK, M.T. (1952). Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Sci. Proc. Am. Assoc. Cancer Res. 12, 264.
19. GINN, S.L., FLEMING, J., ROWE, P.B., and ALEXANDER, I.E. (2003). Promoter interference mediated by the U3 region in early-generation HIV-1-derived lentivirus vectors can influence detection of transgene expression in a cell-type and species-specific manner. Hum. Gene Ther. 14, 1127-1137.
20. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
21. HABERMAN, R.P., MCCOWN, T.J., and SAMULSKI, R.J. (1998). Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther. 5, 1604-1611.
22. HARDING, A.E. (1981). Friedreich's ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104, 589-620.
23. HAUSSE, A.O., AGGOUN, Y., BONNET, D., SIDI, D., MUNNICH, A., ROTIG, A., and RUSTIN, P. (2002). Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87, 346-349.
24. HUGHES, J.T., BROWNELL, B., and HEWER, R.L. (1968). The peripheral sensory pathway in Friedreich's ataxia: An examination by light and electron microscopy of the posterior nerve roots, posterior root ganglia, and peripheral sensory nerves in cases of Friedreich's ataxia. Brain 91, 803-818.
25. JAUSLIN, M.L., WIRTH, T., MEIER, T., and SCHOUMACHER, F. (2002). A cellular model for Friedreich ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum. Mol. Genet. 11, 3055-3063.
26. JAUSLIN, M.L., MEIER, T., SMITH, R.A., and MURPHY, M.P. (2003). Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 17, 1972-1974.
27. KARTHIKEYAN, G., SANTOS, J.H., GRAZIEWICZ, M.A., COPELAND, W.C., ISAYA, G., VAN HOUTEN, B., and RESNICK, M.A. (2003). Reduction in frataxin causes progressive accumulation of mitochondrial damage. Hum. Mol. Genet. 12, 3331-3342.
28. KORDOWER, J.H., EMBORG, M.E., BLOCH, J., MA, S.Y., CHU, Y., LEVENTHAL, L., MCBRIDE, J., CHEN, E.Y., PALFI, S., ROITBERG, B.Z., BROWN, W.D., HOLDEN, J.E., PYZALSKI, R., TAYLOR, M.D., CARVEY, P., LING, Z., TRONO, D., HANTRAYE, P., DEGLON, N., and AEBISCHER, P. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773.
29. LODI, R., COOPER, J.M., BRADLEY, J.L., MANNERS, D., STYLES, P., TAYLOR, D.J., and SCHAPIRA, A.H. (1999). Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl. Acad. Sci. U.S.A. 96, 11492-11495.
30. MANDEL, R.J., RENDAHL, K.G., SPRATT, S.K., SNYDER, R.O., COHEN, L.K., and LEFF, S.E. (1998). Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J. Neurosci. 18, 4271-4284.
31. MAZARAKIS, N.D., AZZOUZ, M., ROHLL, J.B., ELLARD, P.M., WILKES, F.J., OLSEN, A.L., CARTER, E.E., BARBER, R.D., BABAN, D.F., KINGSMAN, S.M., KINGSMAN, A.J., O'MALLEY, K., and MITROPHANOUS, K.A. (2001). Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10, 2109-2121.
32. MIRANDA, C.J., SANTOS, M.M., OHSHIMA, K., TESSARO, M., SEQUEIROS, J., and PANDOLFO, M. (2004). Frataxin overexpressing mice. FEBS Lett. 572, 281-288.
33. MUHLENHOFF, U., RICHHARDT, N., RISTOW, M., KISPAL, G., and LILL, R. (2002). The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum. Mol. Genet. 11, 2025-2036.
34. MUZYCZKA, N. (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158, 97-129.
35. POOK, M.A., AL MAHDAWI, S., CARROLL, C.J., COSSEE, M., PUCCIO, H., LAWRENCE, L., CLARK, P., LOWRIE, M.B., BRADLEY, J.L., COOPER, J.M., KOENIG, M., and CHAMBERLAIN, S. (2001). Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis. Neurogenetics 3, 185-193.
36. PRILLER, J., SCHERZER, C.R., FABER, P.W., MACDONALD, M.E., and YOUNG, A.B. (1997). Frataxin gene of Friedreich's ataxia is targeted to mitochondria. Ann. Neurol. 42, 265-269.
37. PUCCIO, H., SIMON, D., COSSEE, M., CRIQUI-FILIPE, P., TIZIANO, F., MELKI, J., HINDELANG, C., MATYAS, R., RUSTIN, P., and KOENIG, M. (2001). Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27, 181-186.
38. RICHARDSON, D.R. (2004). Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann N.Y. Acad. Sci. 1012, 326-341.
39. RISTOW, M., PFISTER, M.F., YEE, A.J., SCHUBERT, M., MICHAEL, L., ZHANG, C.Y., UEKI, K., MICHAEL, M.D., LOWELL, B.B., and KAHN, C.R. (2000). Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 97, 12239-12243.
40. RUSSELL, D.W., MILLER, A.D., and ALEXANDER, I.E. (1994). Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. U.S.A. 91, 8915-8919.
41. RUSTIN, P., KLEIST-RETZOW, J.C., CHANTREL-GROUSSARD, K., SIDI, D., MUNNICH, A., and ROTIG, A. (1999). Effect of idebenone on cardiomyopathy in Friedreich's ataxia: A preliminary study. Lancet 354, 477-479.
42. SARSERO, J.P., LI, L., WARDAN, H., SITTE, K., WILLIAMSON, R., and IOANNOU, P.A. (2003). Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J. Gene Med. 5, 72-81.
43. SASTRY, L., JOHNSON, T., HOBSON, M.J., SMUCKER, B., and CORNETTA, K. (2002). Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods. Gene Ther. 9, 1155-1162.
44. SEZNEC, H., SIMON, D., MONASSIER, L., CRIQUI-FILIPE, P., GANSMULLER, A., RUSTIN, P., KOENIG, M., and PUCCIO, H. (2004). Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum. Mol. Genet. 13, 1017-1024.
45. SIMON, D., SEZNEC, H., GANSMULLER, A., CARELLE, N., WEBER, P., METZGER, D., RUSTIN, P., KOENIG, M., and PUCCIO, H. (2004). Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J. Neurosci. 24, 1987-1995.
46. TAN, G., NAPOLI, E., TARONI, F., and CORTOPASSI, G. (2003). Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum. Mol. Genet. 12, 1699-1711.
47. TENENBAUM, L., CHTARTO, A., LEHTONEN, E., VELU, T., BROTCHI, J., and LEVIVIER, M. (2004). Recombinant AAV-mediated gene delivery to the central nervous system. J. Gene Med. 6(Suppl. 1), S212-S222.
48. VELDWIJK, M.R., TOPALY, J., LAUFS, S., HENGGE, U.R., WENZ, F., ZELLER, W.J., and FRUEHAUF, S. (2002). Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther. 6, 272-278.
49. VONCKEN, M., IOANNOU, P., and DELATYCKI, M.B. (2004). Friedreich ataxia: Update on pathogenesis and possible therapies. Neurogenetics 5, 1-8.
50. WONG, A., YANG, J., CAVADINI, P., GELLERA, C., LONNERDAL, B., TARONI, F., and CORTOPASSI, G. (1999). The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8, 425-430.
51. WOOLF, C.J., and MANNION, R.J. (1999). Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet 353, 1959-1964.
52. XIAO, X., LI, J., and SAMULSKI, R.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232.
53. YOUNG, R.R. (1994). Spasticity: A review. Neurology 44, S12-S20.